Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of pertuzumab monotherapy or combination therapy after prior Roche-sponsored pertuzumab trials
jRCT2080224110Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of pertuzumab in breast cancer, sponsored by Chugai Pharmaceutical Co., Ltd. Started Oct 2018; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080224110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224110.